Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study

Kumar, S., Dispenzieri, A., Bhutani, D., Gertz, M., Wechalekar, A., Palladini, G., Comenzo, R., Fonseca, R., Jaccard, A., Kastritis, E., Schönland, S., la Porte, C., Pei, H., Tran, N., & Merlini, G. (2023). Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. Amyloid, 30(3), 268–278. https://doi.org/10.1080/13506129.2022.2164488
Authors:
Shaji Kumar
Angela Dispenzieri
Divaya Bhutani
Morie Gertz
Ashutosh Wechalekar
Giovanni Palladini
Raymond Comenzo
Rafael Fonseca
Arnaud Jaccard
Efstathios Kastritis
Stefan Schönland
Charles la Porte
Huiling Pei
NamPhuong Tran
Giampaolo Merlini
Affiliated Authors:
Divaya Bhutani
Columbia Affiliation:
Subjects:
Immunoglobulin Light-chain Amyloidosis (MeSH)
Author Keywords:
haematologic response
al amyloidosis
cytogenetic
daratumumab
organ response
elink
Publication Type:
Article
Unique ID:
10.1080/13506129.2022.2164488
PMID:
36779691
DOI:
10.1080/13506129.2022.2164488
Journal:
Amyloid
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: